Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cutaneous lymphomas].

Hervé Bachelez1

  • 1Service de dermatologie 1 et unité Inserm U697, hôpital Saint-Louis, 75475 Paris. herve.bachelez@sls.aphp.fr

La Revue Du Praticien
|June 23, 2007
PubMed
Summary
This summary is machine-generated.

Cutaneous lymphoma, a diverse group of skin cancers, shows varied prognoses. Newer biologic therapies offer improved outcomes for aggressive forms, enhancing patient outlook.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global burden of skin and subcutaneous disease across childhood and adolescence in 204 countries and territories, 1990-2021.

JAAD international·2026
Same author

Psoriasis flare-ups in non syndromic autosomal recessive epidermal differentiation disorders.

The British journal of dermatology·2026
Same author

Switching from intravenous to subcutaneous infliximab in hidradenitis suppurativa: A French multicenter retrospective study.

Journal of the American Academy of Dermatology·2026
Same author

Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis.

NEJM evidence·2026
Same author

CD73<sup>high</sup> fibroblasts orchestrate keratinocyte inflammation in the psoriasis-associated epithelial immune microenvironment.

Nature communications·2026
Same author

The Psoriatic Disease Assessment Index (PSODAI) Score to Evaluate Systemic Involvement of Psoriasis.

Psoriasis (Auckland, N.Z.)·2026
Same journal

[Prolonged fever].

La Revue du praticien·2026
Same journal

[Lower gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[A history of child abuse intervention in the West].

La Revue du praticien·2026
Same journal

[Agranulocytose médicamenteuse].

La Revue du praticien·2026
Same journal

[Patient education in heart failure].

La Revue du praticien·2026
See all related articles

Area of Science:

  • Oncology
  • Dermatology
  • Immunology

Context:

  • Cutaneous lymphoma presents diverse clinical, pathological, and molecular features.
  • Classification emphasizes prognostic implications of distinct subtypes.
  • Low-grade forms have effective treatments and favorable prognoses.

Purpose:

  • To review the heterogeneity of cutaneous lymphoma.
  • To highlight recent therapeutic advancements.
  • To discuss future therapeutic perspectives based on molecular mechanisms.

Summary:

  • Recent classifications of cutaneous lymphoma consider specific features impacting prognosis.
  • Novel biologic therapies, such as rituximab and alemtuzumab, are improving outcomes for severe and refractory cases.
  • Understanding molecular drivers promises new treatment strategies.

Related Experiment Videos

Impact:

  • Advances in understanding and classifying cutaneous lymphoma are crucial for patient management.
  • Targeted biologic therapies are transforming treatment paradigms for aggressive cutaneous lymphomas.
  • Future research into molecular mechanisms will likely yield novel therapeutic targets.